Wahed FTSE USA Shariah ETF vs Oruka Therapeutics Inc. Common Stock — how do they compare? Wahed FTSE USA Shariah ETF trades at $74.2 (market cap $996.16M), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 5.2× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 67 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HLAL | ORKA | |
|---|---|---|
Market Cap | $996.16M | $5.18B |
Volume | 36,084 | 490,798 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $113.08 |
52-Week Low | $57.46 | $26.19 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $4.31B |
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.90, showing modest daily gains of 0.13% with a bullish technical outlook supported by moving averages. The stock faces resistance near $77-78 while finding support at $75-74 levels. Key technical indicators show mixed signals with RSI suggesting potential overbought conditions on shorter timeframes.
Investment outlook remains data-dependent given limited fundamental information availability. The technical setup suggests near-term upside potential if resistance levels are breached, though momentum indicators warrant caution. Investors should await upcoming financial disclosures for clearer fundamental assessment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →